A R MEDICS LIMITED
No material changes in the last 30 days.
No snapshot from 90 days ago — start tracking from today.
No snapshot from 180 days ago — start tracking from today.
Opportunity 75/100 (strong), bankability 75/100. High owner-dependency — earn-out structure likely required for clean transition. Share purchase looks the cleaner deal structure. Biggest value-creation lever: Broaden director team. Sole director creates succession risk and reduces buyer comfort. Appoint a second director or strong #2. Most likely exit: strategic trade sale (65/100).
Data confidence
Overall: medium (79/100)Adequate coverage. AI outputs are reliable for the sections scored high; verify the rest in diligence.
Solid opportunity signal. Worth a dedicated memo and management meeting.
Signals from accounts
Derived from iXBRL accounts · FRS 102Key financials
2 years extracted from filed iXBRL accountsHover to see exact values · click legend to toggle series
Financials
Extracted from Companies House accounts · FRS 102| Metric | 2024-11-30 | 2023-11-30 |
|---|---|---|
| Total assets | £-11.5k | £-10.0k |
| Current assets | £1.3k | £635 |
| Cash | £1.3k | £635 |
| Net assets | £-11.5k | £-10.0k |
Amounts extracted automatically from iXBRL. Fields left blank were not reported or not mapped. Values in GBP unless stated.
1 signal detected in this company's narrative notes — going-concern language, audit opinion, contingent liabilities, related-party transactions.
Available from the Pro tier upwards.
See pricing →Recent activity
Corporate timeline (18 events)Click to expand
- 2025-05-30📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2024-08-29📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2023-08-27📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2022-08-28📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2021-08-28📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2020-09-02📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2019-08-30📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2018-08-30📄accounts-with-accounts-type-total-exemption-fullaccounts · AA
- 2017-08-31📄accounts-with-accounts-type-total-exemption-smallaccounts · AA
- 2016-08-26📄accounts-with-accounts-type-total-exemption-smallaccounts · AA
- 2015-11-16📄annual-return-company-with-made-up-date-full-list-shareholdersannual-return · AR01
- 2015-08-27📄accounts-with-accounts-type-total-exemption-smallaccounts · AA
- 2014-11-06📄annual-return-company-with-made-up-date-full-list-shareholdersannual-return · AR01
- 2014-08-31📄accounts-with-accounts-type-total-exemption-smallaccounts · AA
- 2013-11-22📄annual-return-company-with-made-up-date-full-list-shareholdersannual-return · AR01
- 2008-11-05🏢Company incorporatedAs A R MEDICS LIMITED
- 2008-11-05➕FAISAL, Fareeha, Dr appointedsecretary
- 2008-11-05➕AKHTAR, Muhammad Faisal, Doctor appointeddirector
Owner dependency
The business appears inseparable from the founder. Acquisition without a serious earn-out or meaningful transition period would likely destroy value.
- +Sole director: Only one active director — all governance concentrated on one person.
- +Long-tenure founder: Senior director has been in place 18 years — deep operational knowledge concentrated in one person.
- +No director turnover: Company is 18 years old with no director changes — suggests a very tight-knit founder team never broadened.
Succession & seller-readiness
Multiple signals suggest succession is on the horizon. Candidate for proactive outreach.
- primarySole active director: Only one director in control. No visible successor — buyers solve the succession problem.
- secondary12+ year tenure: Director in role 18 years.
- secondaryStable-but-static management: Company is 18 years old and no new directors in the last 3 years — succession not yet being planned internally.
- supportingClean filings + long tenure: Disciplined long-tenure operator — classic lifestyle-business pattern that often sells quietly.
Red flags
cleanShareholders & ownership
1 active beneficial owner| Name | Shares | Voting rights | Nature of control | Notified |
|---|---|---|---|---|
Dr Fareeha Faisal Individual · British · DOB 11/1977 · age 49 | 25–50% | — | 25-50% shares | 01/11/2016 |
From Companies House Persons with Significant Control filings. Share ranges are banded per the public PSC regime.
Radial SVG graph showing every company connected via shared directors, colour-coded by status.
Available from the Pro tier upwards.
See pricing →Similar companies
Active · Healthcare & medical · LA postcode area| Company | Est. value | Turnover | Net worth | Staff | Age | Opp | Director |
|---|---|---|---|---|---|---|---|
| ACS HEALTH LIMITED→ 14043891 · est 2022 · no financials extracted | — | — | — | — | 4y | — | — |
| AJM SMILE AND AESTHETICS LIMITED→ 12739020 · est 2020 · no financials extracted | — | — | — | — | 5y | — | — |
| ANGELA HADWIN & ASSOCIATES LTD→ 15013471 · est 2023 · no financials extracted | — | — | — | — | 2y | — | — |
| APPLETREE TREATMENT CENTRE LIMITED→ 03838620 · est 1999 · no financials extracted | — | — | — | — | 26y | — | — |
| ARK CARE GROUP LIMITED→ 16187071 · est 2025 · no financials extracted | — | — | — | — | 1y | — | — |
| ARYADYA LTD→ 11315099 · est 2018 · no financials extracted | — | — | — | — | 8y | — | — |
| ASHMOOR HEALTH CARE LIMITED→ 04531409 · est 2002 · no financials extracted | — | — | — | — | 23y | — | — |
| AUTUMN BLOSSOMS LTD→ 10718191 · est 2017 · no financials extracted | — | — | — | — | 9y | — | — |
| B&C SURGICAL SERVICES LIMITED→ 14325354 · est 2022 · no financials extracted | — | — | — | — | 3y | — | — |
| BALLDENT LTD→ 13221993 · est 2021 · no financials extracted | — | — | — | — | 5y | — | — |
| BARDEN HOUSE LIMITED→ 13411574 · est 2021 · no financials extracted | — | — | — | — | 4y | — | — |
| BARE DENTAL CLINIC LIMITED→ 09668710 · est 2015 · no financials extracted | — | — | — | — | 10y | — | — |
7 specific questions generated from this company's actual signals — liquidity, leverage, director age, charge count, red flags, age-of-company.
Available from the Pro tier upwards.
See pricing →Exit-route ranking, improvement thesis, quiet-distress detector, covenant-pressure proxy, extraction monitor, approaching triggers, ownership drift, local cluster, value trap, debt capacity, archetype classification — 48+ scoring modules.
Available from the Pro tier upwards.
See pricing →Company details
Registered office
Filing status
Officers (2 active · 0 resigned)
Click a director name to see their full track record across all companies.